Antibody response to rabies pre-exposure vaccination among village health volunteers in a northern region of Thailand

Khamduang, Woottichai; Hongjaisee, Sayamon; Pothita, Tippayathida; Kongyai, Natedao; Surajinda, Sirithorn; Petsophonsakul, Wilaiwan; Pornprasert, Sakorn

doi:10.1016/j.prevetmed.2021.105555

Cited by 3 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a single ID booster dose was sufficient to increase the level of anti-rabies antibody. These data are consistent with those of a previous study of Thai VHVs and LVs [ 10 ]. Another study showed that rabies antibodies persisted for many years after ID PrEP, and an adequate antibody response could be expected 7 days after a single ID booster dose in more than 99% of participants; however, the participants in this study were vaccinated with a standard schedule (three 0.1-ml doses) and a modified schedule (five 0.1-mL doses) [ 15 ].…”

Section: Discussionsupporting

confidence: 93%

“…The adverse events after each injection tended to decrease after the 1st and 2nd booster doses. The safety and tolerability of the treatments in the study groups appeared to be consistent with those of previous studies using these vaccines and regimens [ 10 , 13 ].…”

Section: Discussionsupporting

confidence: 82%

“…We confirmed that the participants were primed after receiving a cost-saving rabies PrEP vaccination independent of the achievement of seroconversion (anti-rabies antibody ≥ 0.7 EU/mL) as determined using the CEE-cELISA procedures from our previous study [ 11 ]. Our other study provided evidence that CEE-cELISA is suitable for monitoring antibodies against the rabies virus in the serum of humans compared with RFFIT results and revealed a very strong correlation between CEE-cELISA and RFFIT data [ 10 ]. Moreover, RVGP serology ELISA has been proven to be able to measure neutralizing antibodies in the sera of vaccinated humans in a double-blind test by the RFFIT, and the specificity and sensitivity were 100% and 91.1%, respectively [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

“…Fewer injection regimens would also facilitate rabies vaccination among high-risk village volunteers who are at risk of being exposed to rabies virus every year. As such, one ID dose of the booster regimen was applied to two high-risk village volunteers who had been vaccinated with cost-saving PrEP one year before vaccination and who showed an adequate level of anti-rabies antibody on day 30 after vaccination [ 10 ]. However, the boosting ability and persistence of adequate antibodies in response to a single ID dose of booster agent are still underdetermined.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

One-dose intradermal rabies booster enhances rabies antibody production and avidity maturation

Kewcharoenwong,

Freeouf,

Nithichanon

et al. 2024

Med Microbiol Immunol

Self Cite

View full text Add to dashboard Cite

The incidence of rabies in Thailand reached its peak in 2018 with 18 human deaths. Preexposure prophylaxis (PrEP) vaccination is thus recommended for high-risk populations. WHO has recently recommended that patients who are exposed to a suspected rabid animal and have already been immunized against rabies should receive a 1-site intradermal (ID) injection of 0.1 mL on days 0 and 3 as postexposure prophylaxis (PEP). In Thailand, village health and livestock volunteers tasked with annual dog vaccination typically receive only a single lifetime PrEP dose and subsequent boosters solely upon confirmed animal bites. However, the adequacy of a single PrEP dose for priming and maintaining immunity in this high-risk group has not been evaluated. Therefore, our study was designed to address two key questions: (1) sufficiency of single-dose PrEP—to determine whether a single ID PrEP dose provides adequate long-term immune protection for high-risk individuals exposed to numerous dogs during their vaccination duties. (2) Booster efficacy for immune maturation—to investigate whether one or two additional ID booster doses effectively stimulate a mature and sustained antibody response in this population. The level and persistence of the rabies antibody were determined by comparing the immunogenicity and booster efficacy among the vaccination groups. Our study demonstrated that rabies antibodies persisted for more than 180 days after cost-effective ID PrEP or the 1st or the 2nd single ID booster dose, and adequate antibody levels were detected in more than 95% of participants by CEE-cELISA and 100% by indirect ELISA. Moreover, the avidity maturation of rabies-specific antibodies occurred after the 1st single ID booster dose. This smaller ID booster regimen was sufficient for producing a sufficient immune response and enhancing the maturation of anti-rabies antibodies. This safe and effective PrEP regimen and a single visit involving a one-dose ID booster are recommended, and at least one one-dose ID booster regimen could be equitably implemented in at-risk people in Thailand and other developing countries. However, an adequate antibody level should be monitored before the booster is administered.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

One-dose intradermal rabies booster enhances rabies antibody production and avidity maturation

Kewcharoenwong,

Freeouf,

Nithichanon

et al. 2024

Med Microbiol Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The antibody levels were determined in village volunteers who had received the current rabies PrEP recommended by WHO in 2018 (two intradermal doses provided 7 days apart). With this economical strategy, 92% of the vaccinated individuals had an adequate antibody titre (> 0.5 EU/ml) with a median of 12.4 EU/ml (Khamduang et al, 2022). Thus, the new WHO recommendation is effective for pre-exposure vaccination.…”

Section: Challenge Iv: Evaluating Rabies Vaccination In High-risk Exp...mentioning

confidence: 95%

One Health for Dog-mediated Rabies Elimination in Asia

2023

View full text Add to dashboard Cite

The views expressed in this publication are those of the author(s) and do not necessarily represent those of, and should not be attributed to, CAB International (CABI). Any images, figures and tables not otherwise attributed are the author(s)' own. References to internet websites (URLs) were accurate at the time of writing. CAB International and, where different, the copyright owner shall not be liable for technical or other errors or omissions contained herein. The information is supplied without obligation and on the understanding that any person who acts upon it, or otherwise changes their position in reliance thereon, does so entirely at their own risk. Information supplied is neither intended nor implied to be a substitute for professional advice. The reader/user accepts all risks and responsibility for losses, damages, costs and other consequences resulting directly or indirectly from using this information. CABI's Terms and Conditions, including its full disclaimer, may be found at https://www.cabi.org/ terms-and-conditions/.

show abstract

One Health Approach to Control Canine Rabies in Thailand: The Chiang Mai Model

Petsophonsakul

Inoue

2023

One Health for Dog-Mediated Rabies Elimination in Asia

View full text Add to dashboard Cite

Antibody response to rabies pre-exposure vaccination among village health volunteers in a northern region of Thailand

Cited by 3 publications

References 10 publications

One-dose intradermal rabies booster enhances rabies antibody production and avidity maturation

One-dose intradermal rabies booster enhances rabies antibody production and avidity maturation

One Health for Dog-mediated Rabies Elimination in Asia

One Health Approach to Control Canine Rabies in Thailand: The Chiang Mai Model

Contact Info

Product

Resources

About